Potassium Citrate

Identification

Name
Potassium Citrate
Accession Number
DB09125
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Structure
Thumb
Synonyms
  • tripotassium citrate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet5 meq/1OralUpsher Smith Laboratories, Llc2006-09-01Not applicableUs00245 0070 11 nlmimage10 234691d4
Potassium CitrateTablet10 meq/1OralUpsher Smith Laboratories, Llc2006-09-01Not applicableUs00245 0071 11 nlmimage10 f00df86f
Urocit KTablet, extended release540 mgOralMission Pharmacal1995-01-01Not applicableCanada
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUs
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal1985-09-01Not applicableUs
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal2010-01-27Not applicableUs
Urocit-KTablet, extended release10 meq/1OralRemedy Repack2016-12-27Not applicableUs
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs00178 0615 01 nlmimage10 581dac0d
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal1992-09-01Not applicableUs
Urocit-KTablet, extended release1080 mgOralMission Pharmacal2011-02-11Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUs44523 0415 01 nlmimage10 4a3ea535
Potassium CitrateTablet, extended release5 meq/1OralActavis Pharma Company2018-05-30Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralAmerincan Health Packaging2014-10-01Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralActavis Pharma Company2018-05-30Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release1080 mg/1OralPhysicians Total Care, Inc.2006-07-24Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralActavis Pharma Company2018-05-30Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
B6 Plus TabPotassium Citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada
Formula No. 2 Plus K LiqPotassium Citrate (19.5 mg) + Ascorbic acid (2 mg)LiquidOralGolden Pride/Rawleigh1993-12-311996-09-30Canada
LytrenPotassium Citrate (270 mg) + Citric Acid (26 mg) + Dextrose, unspecified form (2 g) + Sodium Chloride (263 mg) + Sodium Citrate (49 mg)LiquidOralMead Johnson Nutritionals1985-12-312003-07-08Canada
Lytren Rhs LiqPotassium Citrate (217 mg) + Citric Acid (26.1 mg) + Sodium Chloride (375 mg) + Sodium Citrate (107 mg)LiquidOralMead Johnson Nutritionals1990-12-312000-09-11Canada
RehydralytePotassium Citrate (2.04 mg) + Dextrose, unspecified form (25 mg) + Sodium Chloride (3.8 mg) + Sodium Citrate (.78 mg)LiquidOralRoss Laboratories, Division Of Abbott Laboratories Ltd.1988-12-312008-04-16Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cytra-K CrystalsPotassium Citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceuticals, Inc.2003-05-01Not applicableUs
Potassium Citrate and Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralPharmaceutical Associates, Inc.1997-10-07Not applicableUs
Potassium Citrate Citric Acid CrystalsPotassium Citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralVirtus Pharmaceuticals2014-06-13Not applicableUs
Potassium Citrate-Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31Us
Potassium Citrate-Citric AcidPotassium Citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-05Us
Potassium Citrate-Sodium Citrate-Citric AcidPotassium Citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31Us
Potassium Citrate-Sodium Citrate-Citric AcidPotassium Citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-05Us
TricitratesPotassium Citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium Citrate (500 mg/5mL)SolutionOralPharmaceutical Associates, Inc.2005-05-25Not applicableUs
Categories
UNII
86R1NVR0HW
CAS number
Not Available
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Associated Conditions
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half life
Not Available
Clearance
Not Available
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Potassium Citrate.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Potassium Citrate.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Potassium Citrate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Potassium Citrate.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium Citrate.Approved, Illicit
AllylestrenolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Potassium Citrate.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Potassium Citrate.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium Citrate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Potassium Citrate.Illicit
AlprostadilAlprostadil may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Potassium Citrate.Approved
AltrenogestThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Altrenogest.Vet Approved
Aluminum hydroxidePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
AmilorideThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Potassium Citrate.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Potassium Citrate.Approved
AncrodAncrod may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Potassium Citrate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Potassium Citrate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Potassium Citrate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Antithrombin III humanAntithrombin III human may increase the anticoagulant activities of Potassium Citrate.Approved
ApixabanApixaban may increase the anticoagulant activities of Potassium Citrate.Approved
ApocyninApocynin may increase the anticoagulant activities of Potassium Citrate.Investigational
ApremilastApremilast may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
ArdeparinArdeparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Potassium Citrate.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Potassium Citrate.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Potassium Citrate.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Azficel-T.Approved, Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Potassium Citrate.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
BenazeprilPotassium Citrate may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Potassium Citrate.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Potassium Citrate.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Potassium Citrate.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Potassium Citrate.Approved
BeraprostBeraprost may increase the anticoagulant activities of Potassium Citrate.Investigational
BevoniumBevonium may increase the anticoagulant activities of Potassium Citrate.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium Citrate.Experimental, Illicit, Withdrawn
BisacodylThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Bisacodyl.Approved
BivalirudinBivalirudin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Potassium Citrate.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Potassium Citrate.Approved
BucillamineBucillamine may increase the anticoagulant activities of Potassium Citrate.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Potassium Citrate.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Potassium Citrate.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Potassium Citrate.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.Approved, Illicit, Vet Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Potassium Citrate.Investigational
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Potassium Citrate.Approved
CandoxatrilPotassium Citrate may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Potassium Citrate.Approved
Canrenoic acidThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Canrenone.Investigational
CaplacizumabCaplacizumab may increase the anticoagulant activities of Potassium Citrate.Investigational
CaptoprilPotassium Citrate may increase the hyperkalemic activities of Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Potassium Citrate.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium Citrate.Illicit, Investigational, Vet Approved
CarprofenCarprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved, Withdrawn
CarvedilolThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the anticoagulant activities of Potassium Citrate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
CertoparinCertoparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
ChlormadinoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Chlormadinone.Experimental
ChloroquineChloroquine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Potassium Citrate.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Potassium Citrate.Approved
CilazaprilPotassium Citrate may increase the hyperkalemic activities of Cilazapril.Approved
ClonixinClonixin may increase the anticoagulant activities of Potassium Citrate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Potassium Citrate.Approved
CloricromenCloricromen may increase the anticoagulant activities of Potassium Citrate.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Potassium Citrate.Experimental
CodeineThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Codeine.Approved, Illicit
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Potassium Citrate.Approved
CurcuminCurcumin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Potassium Citrate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Potassium Citrate.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Potassium Citrate.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
DarexabanDarexaban may increase the anticoagulant activities of Potassium Citrate.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Deferasirox.Approved, Investigational
DelaprilPotassium Citrate may increase the hyperkalemic activities of Delapril.Investigational
DemegestoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Demegestone.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Potassium Citrate.Investigational
DesirudinDesirudin may increase the anticoagulant activities of Potassium Citrate.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Potassium Citrate.Investigational
DesogestrelThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Potassium Citrate.Approved, Investigational
DextranDextran may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium Citrate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium Citrate.Approved, Investigational
DiclofenacThe risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Potassium Citrate.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Potassium Citrate.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational
DienogestThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Potassium Citrate.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.Experimental, Illicit
DiphenadioneDiphenadione may increase the anticoagulant activities of Potassium Citrate.Experimental
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.Approved, Illicit
DipyridamoleDipyridamole may increase the anticoagulant activities of Potassium Citrate.Approved
DitazoleDitazole may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
DocusateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Docusate.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Potassium Citrate.Experimental
DrospirenoneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Potassium Citrate.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Potassium Citrate.Investigational
DydrogesteroneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Potassium Citrate.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Potassium Citrate.Approved
EnalaprilPotassium Citrate may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatPotassium Citrate may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Potassium Citrate.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Potassium Citrate.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Potassium Citrate.Approved
EplerenoneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Potassium Citrate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Potassium Citrate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Potassium Citrate.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Potassium Citrate.Approved
EstroneEstrone may decrease the anticoagulant activities of Potassium Citrate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Potassium Citrate.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Potassium Citrate.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Potassium Citrate.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.Approved, Illicit
EthynodiolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Potassium Citrate.Investigational, Nutraceutical
ExisulindExisulind may increase the anticoagulant activities of Potassium Citrate.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Potassium Citrate.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Potassium Citrate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Potassium Citrate.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the anticoagulant activities of Potassium Citrate.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Potassium Citrate.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Potassium Citrate.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Potassium Citrate.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
FluindioneFluindione may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Potassium Citrate.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Potassium Citrate.Experimental
FluoxetineFluoxetine may increase the antiplatelet activities of Potassium Citrate.Approved, Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
FluvoxamineFluvoxamine may increase the antiplatelet activities of Potassium Citrate.Approved, Investigational
FondaparinuxFondaparinux sodium may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
FosinoprilPotassium Citrate may increase the hyperkalemic activities of Fosinopril.Approved
GabexateGabexate may increase the anticoagulant activities of Potassium Citrate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Potassium Citrate.Investigational
GestodeneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Gestrinone.Approved
GlycerinThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Glycerin.Approved, Investigational
GuacetisalGuacetisal may increase the anticoagulant activities of Potassium Citrate.Experimental
HeminHemin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Potassium Citrate.Experimental
HeparinHeparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium Citrate.Approved, Illicit, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Potassium Citrate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Potassium Citrate.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.Approved, Illicit
Hydroxyprogesterone caproateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Potassium Citrate.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Potassium Citrate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
IbuprofenThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Potassium Citrate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Potassium Citrate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Potassium Citrate.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Potassium Citrate.Investigational
IloprostIloprost may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
ImidaprilPotassium Citrate may increase the hyperkalemic activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Potassium Citrate.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Potassium Citrate.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Potassium Citrate.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Potassium Citrate.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Potassium Citrate.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Potassium Citrate.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Potassium Citrate.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
LepirudinPotassium Citrate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanLetaxaban may increase the anticoagulant activities of Potassium Citrate.Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Potassium Citrate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Potassium Citrate.Experimental
LisinoprilPotassium Citrate may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Potassium Citrate.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium Citrate.Illicit
LonazolacLonazolac may increase the anticoagulant activities of Potassium Citrate.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
LynestrenolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Lynestrenol.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Potassium Citrate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Potassium Citrate.Approved
Megestrol acetateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranMelagatran may increase the anticoagulant activities of Potassium Citrate.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Potassium Citrate.Experimental
MesalazineMesalazine may increase the anticoagulant activities of Potassium Citrate.Approved
MestranolMestranol may decrease the anticoagulant activities of Potassium Citrate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium Citrate.Approved, Illicit
MethallenestrilMethallenestril may decrease the anticoagulant activities of Potassium Citrate.Experimental
Methyl salicylateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Potassium Citrate.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Methylestrenolone.Experimental
MetoprololThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Metoprolol.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Potassium Citrate.Approved
Mineral oilThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Mineral oil.Approved, Vet Approved
MizoribineMizoribine may increase the anticoagulant activities of Potassium Citrate.Investigational
MoexiprilPotassium Citrate may increase the hyperkalemic activities of Moexipril.Approved
MofebutazoneMofebutazone may increase the anticoagulant activities of Potassium Citrate.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.Approved, Investigational
MoxestrolMoxestrol may decrease the anticoagulant activities of Potassium Citrate.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Potassium Citrate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Potassium Citrate.Approved
NadroparinNadroparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Potassium Citrate.Approved
NaftopidilThe risk or severity of bleeding can be increased when Naftopidil is combined with Potassium Citrate.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.Approved
NaproxenThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Potassium Citrate.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Potassium Citrate.Experimental
NifenazoneNifenazone may increase the anticoagulant activities of Potassium Citrate.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Potassium Citrate.Approved
NimesulideThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Potassium Citrate.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Potassium Citrate.Investigational
NomegestrolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Norgestrienone.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium Citrate.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Potassium Citrate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Potassium Citrate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Potassium Citrate is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatPotassium Citrate may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Potassium Citrate.Approved, Nutraceutical
Omega-3-carboxylic acidsThe therapeutic efficacy of Potassium Citrate can be increased when used in combination with Omega-3-carboxylic acids.Approved, Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium Citrate.Approved, Illicit
OrgoteinOrgotein may increase the anticoagulant activities of Potassium Citrate.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Potassium Citrate.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Potassium Citrate.Approved
OxycodoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Potassium Citrate.Investigational
PalmidrolPalmidrol may increase the anticoagulant activities of Potassium Citrate.Experimental, Nutraceutical
ParecoxibParecoxib may increase the anticoagulant activities of Potassium Citrate.Approved
ParoxetineParoxetine may increase the antiplatelet activities of Potassium Citrate.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Potassium Citrate.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Potassium Citrate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PerindoprilPotassium Citrate may increase the hyperkalemic activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Potassium Citrate.Experimental
PhenindionePhenindione may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Potassium Citrate.Experimental
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Potassium Citrate.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Potassium Citrate.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Potassium Citrate.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Potassium Citrate.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Potassium Citrate.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Potassium Citrate.Approved, Withdrawn
PranoprofenPranoprofen may increase the anticoagulant activities of Potassium Citrate.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Potassium Citrate.Approved
ProgesteroneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Potassium Citrate.Experimental
PromegestoneThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Potassium Citrate.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Propafenone.Approved
PropranololThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Potassium Citrate.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Potassium Citrate.Experimental
Protein CProtein C may increase the anticoagulant activities of Potassium Citrate.Approved
Protein S humanProtein S human may increase the anticoagulant activities of Potassium Citrate.Approved
ProtocatechualdehydeProtocatechualdehyde may increase the anticoagulant activities of Potassium Citrate.Approved
PTC299PTC299 may increase the anticoagulant activities of Potassium Citrate.Investigational
QuinaprilPotassium Citrate may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Potassium Citrate.Approved
QuingestanolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Quingestanol.Experimental
RamatrobanRamatroban may increase the anticoagulant activities of Potassium Citrate.Investigational
RamiprilPotassium Citrate may increase the hyperkalemic activities of Ramipril.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Potassium Citrate.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.Approved
RescinnaminePotassium Citrate may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Potassium Citrate.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
ReviparinReviparin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Potassium Citrate.Approved
RivaroxabanPotassium Citrate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
SalicylamideSalicylamide may increase the anticoagulant activities of Potassium Citrate.Approved
Salicylic acidThe risk or severity of bleeding can be increased when Salicylic acid is combined with Potassium Citrate.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Potassium Citrate.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Potassium Citrate.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Potassium Citrate.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Potassium Citrate.Approved
SemapimodSemapimod may increase the anticoagulant activities of Potassium Citrate.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Potassium Citrate.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Potassium Citrate.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Potassium Citrate.Approved, Vet Approved
Sodium CitratePotassium Citrate may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicPotassium Citrate may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
SpiraprilPotassium Citrate may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Potassium Citrate.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Potassium Citrate.Approved
SulfasalazineThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Potassium Citrate.Approved
SulindacSulindac may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Potassium Citrate.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Potassium Citrate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Potassium Citrate.Approved
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium Citrate.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Potassium Citrate.Investigational
TemocaprilPotassium Citrate may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Potassium Citrate.Approved
TenidapTenidap may increase the anticoagulant activities of Potassium Citrate.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Potassium Citrate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Potassium Citrate.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Potassium Citrate.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Potassium Citrate.Investigational
Testosterone cypionateThe therapeutic efficacy of Potassium Citrate can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Potassium Citrate can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Potassium Citrate can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Potassium Citrate.Approved
TiboloneTibolone may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Potassium Citrate.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Potassium Citrate.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Potassium Citrate.Experimental
TinoridineTinoridine may increase the anticoagulant activities of Potassium Citrate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Potassium Citrate.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Potassium Citrate.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Potassium Citrate.Approved
Tolfenamic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Potassium Citrate.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Potassium Citrate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Tositumomab.Approved, Investigational
TramadolThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilPotassium Citrate may increase the hyperkalemic activities of Trandolapril.Approved
TranilastThe risk or severity of bleeding can be increased when Tranilast is combined with Potassium Citrate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Potassium Citrate.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
TriamtereneThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Potassium Citrate.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Potassium Citrate.Investigational
Trolamine salicylateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Potassium Citrate.Approved
TroxerutinTroxerutin may increase the anticoagulant activities of Potassium Citrate.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
VenlafaxineVenlafaxine may increase the antiplatelet activities of Potassium Citrate.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Potassium Citrate.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Potassium Citrate.Approved
WarfarinWarfarin may increase the anticoagulant activities of Potassium Citrate.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Potassium Citrate.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Withdrawn
ZofenoprilPotassium Citrate may increase the hyperkalemic activities of Zofenopril.Experimental
ZomepiracZomepirac may increase the anticoagulant activities of Potassium Citrate.Withdrawn
Food Interactions
Not Available

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
External Links
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
ChEBI
64733
ChEMBL
CHEMBL1200458
ATC Codes
A12BA02 — Potassium citrate
AHFS Codes
  • 40:12.00 — Replacement Preparations
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBone Diseases / Metabolic Acidosis / Mineral Metabolism / Physical Capacity / Renal Transplant Patients1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypercalciuria / Renal Stones1
3Unknown StatusPreventionNephrocalcinosis1
4CompletedTreatmentRenal Stones / Urolithiasis1
4RecruitingTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4Unknown StatusTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis (PMO)1
Not AvailableCompletedDiagnosticRenal Stones1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
LiquidOral
TabletOral10 meq/1
TabletOral15 meq/1
TabletOral5 meq/1
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral5 meq/1
Granule, for solutionOral
SolutionOral
Tablet, extended releaseOral540 mg
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1080 mg
Tablet, extended releaseOral15 meq/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Tricarboxylic acid or derivatives / Tertiary alcohol / Carboxylic acid salt / Organic alkali metal salt / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic potassium salt / Organic salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)

Drug created on September 23, 2015 10:41 / Updated on August 14, 2018 04:32